Self-esteem in adolescent patients with attention-deficit/hyperactivity disorder during open-label atomoxetine treatment: psychometric evaluation of the Rosenberg Self-Esteem Scale and clinical findings.
To report on (1) psychometric properties of the Rosenberg Self-Esteem Scale (SES) studied in adolescents with ADHD, (2) correlations of SES with ADHD scale scores, and (3) change in patient-reported self-esteem with atomoxetine treatment. ADHD patients (12-17 years), treated in an open-label study for 24 weeks. Secondary analyses on ADHD symptoms (assessed with ADHD-RS, CGI, GIPD scales) and self-esteem (SES) were performed. One hundred and fifty-nine patients were treated. A dichotomous structure of the SES could be confirmed. Reliability and internal consistency were moderate to excellent. Highest coefficients were found for the correlation between SES and GIPD scores. Self-esteem significantly increased over time, accompanied by an improvement of ADHD symptoms and related perceived difficulties. The Rosenberg SES was shown to be internally consistent, reliable, and sensitive to treatment-related changes of self-esteem. According to these findings, self-esteem may be an important individual patient outcome beyond the core symptoms of ADHD.
Dittmann
Ralf W
RW
Eli Lilly Endowed Chair of Pediatric Psychopharmacology, Department of Child and Adolescent Psychiatry, Central Institute of Mental Health Mannheim, University of Heidelberg, J 5, 68159 Mannheim, Germany. ralf.dittmann@zi-mannheim.de
Wehmeier
Peter M
PM
Schacht
Alexander
A
Lehmann
Martin
M
Lehmkuhl
Gerd
G
D000293:Adolescent; D000294:Adolescent Behavior / Q000187:drug effects*; D018759:Adrenergic Uptake Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D000069445:Atomoxetine Hydrochloride; D001289:Attention Deficit Disorder with Hyperactivity / Q000188:drug therapy* / Q000523:psychology*; D002648:Child; D005163:Factor Analysis, Statistical; D005260:Female; D006801:Humans; D008297:Male; D010552:Personality Assessment; D025341:Principal Component Analysis; D011437:Propylamines / Q000009:adverse effects / Q000627:therapeutic use*; D011594:Psychometrics; D015203:Reproducibility of Results; D012649:Self Concept; D057566:Self Report; D012720:Severity of Illness Index
D018759:Adrenergic Uptake Inhibitors; D011437:Propylamines; D000069445:Atomoxetine Hydrochloride